PCRX News and Press, Pacira BioSciences Inc. From 08/09/22

TAMPA, Fla. and MOUNT LAUREL, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- The National Football League Alumni Association (NFLA), the oldest, most well-known and well-respected retired player organization in professional sports, and Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader i...

Pacira Biosciences Inc. (PCRX) Q2 2022 Results Conference Call August 03, 2022 08:30 AM ET Company Participants Susan Mesco - Head, IR Dave Stack - Chairman, CEO Charlie Reinhart - CFO Conference Call Participants David Amsellem - Piper Sandler Ch...

Pacira BioSciences press release ( NASDAQ: PCRX ): Q2 Non-GAAP EPS of $0.51 misses by $0.34 . Revenue of $169.41M (+24.9% Y/Y) in-line. The company is reiterating its FY2022 operating expense guidance as follows: Non-GAAP R&D expense of $75M to $85M and&...

-- Second quarter revenue of $169 million, increased 25% over prior year, demonstrating successful integration and synergies from Flexion acquisition – -- Strong topline performance delivers solid net income and significantly positive adjusted EBITDA-- -- Conference cal...

Pacira BioSciences ( NASDAQ: PCRX ) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, before market open. The consensus EPS Estimate is $0.85 (+10.4% Y/Y) and the consensus Revenue Estimate is $169.27M (+24.8% Y/Y). Over the last 2 years, PCRX ha...

TAMPA, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference at 11:30 AM ET on Wednesday, August 10, 2022. Live audio of the event...

TAMPA, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Wednesday, August 3, 2022. Following the release, the company will host a live conference cal...

Pacira BioSciences ( NASDAQ: PCRX ) expects Q2 revenues of $169.4M on a preliminary basis, compared to consensus estimate of $174.90M. EXPAREL net product sales were $137M, up from $130.1M in the second quarters of 2021. ZILRETTA sales totaled $27.4M, while iovera sale...

TAMPA, Fla., July 14, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary revenues of $169.4 million for the second quarter of 2022, compared with ...

Baillie Gifford’s 13F portfolio value decreased from ~$182B to ~$143B this quarter. They increased Affirm Holdings, Coupang, and Ginkgo Bioworks while reducing Petroleo Brasileiro and First Republic Bank. The top three positions are Tesla Motors, Moderna, and Illumina, and ...